| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Siddappa A Patil, Renukadevi Patil, Shivaputra A Pati. Recent developments in biological activities of indanones. European journal of medicinal chemistry. vol 138. 2017-09-20. PMID:28667874. |
among the medicinally important indanones, the most significant drug probably is donepezil (iv), an acetylcholinesterase (ache) inhibitor, which has been approved by the us food and drug administration for the treatment of alzheimer's disease (ad). |
2017-09-20 |
2023-08-13 |
Not clear |
| Takamichi Kogure, Masahiko Sumitani, Kiyoshi Ikegami, Hiroaki Abe, Jun Hozumi, Reo Inoue, Kazuo Kawahara, Yoshitsugu Yamad. Donepezil, an Acetylcholinesterase Inhibitor, Can Attenuate Gabapentinoid-Induced Somnolence in Patients with Neuropathic Pain: A Retrospective Chart Review. Journal of pain & palliative care pharmacotherapy. vol 31. issue 1. 2017-09-18. PMID:28287355. |
donepezil, an oral acetylcholinesterase inhibitor, is used to treat alzheimer's disease and reportedly attenuates opioid-induced sedation in patients with cancer pain. |
2017-09-18 |
2023-08-13 |
Not clear |
| Li-Yun Zhou, Yao Zhu, Yu-Ren Jiang, Xiong-Jie Zhao, Dong Gu. Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease. Bioorganic & medicinal chemistry letters. vol 27. issue 17. 2017-09-13. PMID:28751142. |
design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5a inhibitors in treatment for alzheimer's disease. |
2017-09-13 |
2023-08-13 |
Not clear |
| Mariana Matias, Samuel Silvestre, Amílcar Falcao, Gilberto Alve. Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders. Mini reviews in medicinal chemistry. vol 17. issue 6. 2017-09-12. PMID:27834131. |
moreover, several hybrid compounds have also been designed for the treatment of neurodegenerative diseases focusing primarily on alzheimer's disease by targeting the cholinergic neurotransmission, as acetylcholinesterase inhibitors, and the amyloid β-protein deposition. |
2017-09-12 |
2023-08-13 |
Not clear |
| Soledad Fernández, Javier Giglio, Ana Laura Reyes, Andrés Damián, Concepción Pérez, Daniel I Pérez, Mercedes González, Patricia Oliver, Ana Rey, Henry Engler, Hugo Cerecett. 3-(Benzyloxy)-1-(5-[ Future medicinal chemistry. vol 9. issue 10. 2017-09-12. PMID:28632402. |
3-(benzyloxy)-1-(5-[ noninvasive studies of the acetylcholinesterase (ache) level in alzheimer's disease (ad) patients can contribute to a better understanding of the disease and its therapeutic. |
2017-09-12 |
2023-08-13 |
Not clear |
| Sophie J Bradley, Julie-Myrtille Bourgognon, Helen E Sanger, Nicholas Verity, Adrian J Mogg, David J White, Adrian J Butcher, Julie A Moreno, Colin Molloy, Timothy Macedo-Hatch, Jennifer M Edwards, Jurgen Wess, Robert Pawlak, David J Read, Patrick M Sexton, Lisa M Broad, Joern R Steinert, Giovanna R Mallucci, Arthur Christopoulos, Christian C Felder, Andrew B Tobi. M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. The Journal of clinical investigation. vol 127. issue 2. 2017-09-07. PMID:27991860. |
the current frontline symptomatic treatment for alzheimer's disease (ad) is whole-body upregulation of cholinergic transmission via inhibition of acetylcholinesterase. |
2017-09-07 |
2023-08-13 |
mouse |
| A Pourmand, C Shay, W Redha, A Aalam, M Mazer-Amirshah. Cholinergic symptoms and QTc prolongation following donepezil overdose. The American journal of emergency medicine. vol 35. issue 9. 2017-09-07. PMID:28668178. |
donepezil is the most commonly prescribed acetylcholinesterase inhibitor for the treatment of alzheimer's disease, an ailment that affects millions of older adult patients. |
2017-09-07 |
2023-08-13 |
Not clear |
| Slavka Hamulakova, Patrik Poprac, Klaudia Jomova, Vlasta Brezova, Peter Lauro, Lenka Drostinova, Daniel Jun, Vendula Sepsova, Martina Hrabinova, Ondrej Soukup, Pavol Kristian, Zuzana Gazova, Zuzana Bednarikova, Kamil Kuca, Marian Valk. Targeting copper(II)-induced oxidative stress and the acetylcholinesterase system in Alzheimer's disease using multifunctional tacrine-coumarin hybrid molecules. Journal of inorganic biochemistry. vol 161. 2017-09-04. PMID:27230386. |
targeting copper(ii)-induced oxidative stress and the acetylcholinesterase system in alzheimer's disease using multifunctional tacrine-coumarin hybrid molecules. |
2017-09-04 |
2023-08-13 |
Not clear |
| Slavka Hamulakova, Patrik Poprac, Klaudia Jomova, Vlasta Brezova, Peter Lauro, Lenka Drostinova, Daniel Jun, Vendula Sepsova, Martina Hrabinova, Ondrej Soukup, Pavol Kristian, Zuzana Gazova, Zuzana Bednarikova, Kamil Kuca, Marian Valk. Targeting copper(II)-induced oxidative stress and the acetylcholinesterase system in Alzheimer's disease using multifunctional tacrine-coumarin hybrid molecules. Journal of inorganic biochemistry. vol 161. 2017-09-04. PMID:27230386. |
collectively, these results suggest that the design and investigation of multifunctional agents containing along with the acetylcholinesterase inhibitory segment also an antioxidant moiety capable of alleviating metal (copper)-induced oxidative stress, may be of importance in the treatment of alzheimer's disease. |
2017-09-04 |
2023-08-13 |
Not clear |
| Andrew H Ford, Osvaldo P Almeid. Management of Depression in Patients with Dementia: Is Pharmacological Treatment Justified? Drugs & aging. vol 34. issue 2. 2017-08-18. PMID:28074409. |
acetylcholinesterase inhibitors and memantine are effective in the symptomatic treatment of alzheimer's disease but current evidence does not support their use to treat depressive symptoms in dementia. |
2017-08-18 |
2023-08-13 |
Not clear |
| Yan Li, Xiaoming Qiang, Li Luo, Xia Yang, Ganyuan Xiao, Yunxiaozhu Zheng, Zhongcheng Cao, Zhipei Sang, Fu Su, Yong Den. Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties. Bioorganic & medicinal chemistry. vol 25. issue 2. 2017-08-14. PMID:27923535. |
multitarget drug design strategy against alzheimer's disease: homoisoflavonoid mannich base derivatives serve as acetylcholinesterase and monoamine oxidase b dual inhibitors with multifunctional properties. |
2017-08-14 |
2023-08-13 |
Not clear |
| Ramón Cacabelos, Clara Torrellas, Oscar Teijido, Juan Carlos Carri. Pharmacogenetic considerations in the treatment of Alzheimer's disease. Pharmacogenomics. vol 17. issue 9. 2017-08-09. PMID:27291247. |
the practical pharmacogenetics of alzheimer's disease (ad) is circumscribed to acetylcholinesterase inhibitors (acheis) and memantine. |
2017-08-09 |
2023-08-13 |
Not clear |
| Lei Sheng, Yi Qu, Jing Yan, Gang-Yi Liu, Wei-Liang Wang, Yi-Jun Wang, Hong-Yi Wang, Meng-Qi Zhang, Chuan Lu, Yun Liu, Jing-Yin Jia, Chao-Ying Hu, Xue-Ning Li, Chen Yu, Hong-Rong X. Population pharmacokinetic modeling and simulation of huperzine A in elderly Chinese subjects. Acta pharmacologica Sinica. vol 37. issue 7. 2017-08-02. PMID:27180987. |
our preliminary results show that huperzine a, an acetylcholinesterase inhibitor used to treat alzheimer's disease (ad) patients in china, exhibits different pharmacokinetic features in elderly and young healthy subjects. |
2017-08-02 |
2023-08-13 |
human |
| Ludovic Peauger, Rabah Azzouz, Vincent Gembus, Mihaela-Liliana Ţînţaş, Jana Sopková-de Oliveira Santos, Pierre Bohn, Cyril Papamicaël, Vincent Levache. Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a "Bio-Oxidizable" Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation. Journal of medicinal chemistry. vol 60. issue 13. 2017-08-01. PMID:28613859. |
with the aim of reducing side effects of acetylcholinesterase inhibitors (acheis) during symptomatic treatment of alzheimer's disease, we report herein a new class of donepezil-based "bio-oxidizable" prodrugs 1 designed to be converted into dual binding site acheis 2. |
2017-08-01 |
2023-08-13 |
Not clear |
| Laia Calvó-Perxas, Oriol Turró-Garriga, Joan Vilalta-Franch, Manuela Lozano-Gallego, Rosa de Eugenio, Fabián Márquez, Olga Carmona, Jordi Gich, Anna Manzano, Marta Viñas, Anna Mª Roig, Josep Garre-Olm. Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona. Drugs & aging. vol 34. issue 4. 2017-07-31. PMID:28258538. |
acetylcholinesterase inhibitors (acheis) and the n-methyl d-aspartate-antagonist memantine are indicated for the symptomatic treatment of alzheimer's disease (ad). |
2017-07-31 |
2023-08-13 |
Not clear |
| Osamu Imamura, Masaaki Arai, Minori Dateki, Kunio Takishim. Donepezil promotes differentiation of neural stem cells into mature oligodendrocytes at the expense of astrogenesis. Journal of neurochemistry. vol 140. issue 2. 2017-07-28. PMID:27664791. |
previously, using oligodendrocyte progenitor cells, we have shown that donepezil, which is an acetylcholinesterase inhibitor developed for the treatment of alzheimer's disease, stimulates myelin gene expression and oligodendrocyte differentiation. |
2017-07-28 |
2023-08-13 |
mouse |
| Jin Wang, Zhi-Min Wang, Xue-Mei Li, Fan Li, Jia-Jia Wu, Ling-Yi Kong, Xiao-Bing Wan. Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin. Bioorganic & medicinal chemistry. vol 24. issue 18. 2017-07-26. PMID:27460699. |
a novel series of compounds obtained by fusing the acetylcholinesterase (ache) inhibitor donepezil and the antioxidant melatonin were designed as multi-target-directed ligands for the treatment of alzheimer's disease (ad). |
2017-07-26 |
2023-08-13 |
Not clear |
| Yunqin Zhang, Shuqun Zhang, Guowei Xu, Hui Yan, Yinglan Pu, Zhili Zu. The discovery of new acetylcholinesterase inhibitors derived from pharmacophore modeling, virtual screening, docking simulation and bioassays. Molecular bioSystems. vol 12. issue 12. 2017-07-24. PMID:27801451. |
hyperactivity of acetylcholinesterase (ache) in the brain is the immediate cause of alzheimer's disease (ad), which is one of the most prevalent fatal diseases afflicting numerous older people. |
2017-07-24 |
2023-08-13 |
Not clear |
| Kouki Makitani, Shota Nakagawa, Yasuhiko Izumi, Akinori Akaike, Toshiaki Kum. Inhibitory effect of donepezil on bradykinin-induced increase in the intracellular calcium concentration in cultured cortical astrocytes. Journal of pharmacological sciences. vol 134. issue 1. 2017-07-13. PMID:28499726. |
donepezil is a potent and selective acetylcholinesterase inhibitor developed for the treatment of alzheimer's disease. |
2017-07-13 |
2023-08-13 |
Not clear |
| Mariana Vázquez García, Gilsane Lino von Poser, Miriam Apel, Rosa Cerros Tlatilpa, Aniceto Mendoza-Ruiz, María Luisa Villarreal, Amelia Teresinha Henriques, Alexandre Cardoso Taket. Anticholinesterase activity and identification of huperzine A in three Mexican lycopods: Huperzia cuernavacensis, Huperzia dichotoma and Huperzia linifolia (Lycopodiaceae). Pakistan journal of pharmaceutical sciences. vol 30. issue 1 Suppl. 2017-07-10. PMID:28625948. |
huperzine a (hup a), the alkaloid produced by the chinese medicinal plant huperzia serrata, has been documented to be a promising agent for the treatment of alzheimer's disease due to its potent acetylcholinesterase inhibitory (achei) activity. |
2017-07-10 |
2023-08-13 |
Not clear |